ArticleJournal of hepatocellular carcinoma2025
Prognostic Value of Gd-BOPTA Enhanced MRI in Solitary Resected Hepatocellular Carcinoma Without Microvascular Invasion.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the prognostic predictive efficacy of Gadobenate dimeglumine (Gd-BOPTA)-enhanced magnetic resonance imaging (MRI) in patients with solitary hepatocellular carcinoma (HCC) without microvascular invasion (MVI) and to investigate the potential clinical and imaging parameters for stratifying the risk of recurrence following hepatectomy. Methods: This retrospective study included 134 patients with histopathologically confirmed solitary HCC without microvascular invasion (MVI) from two hospital districts, which divided into the training cohort and validation cohort. MRI features were independently assessed by two radiologists. Univariate and multivariate Cox regression analyses were conducted to identify independent risk factors associated with recurrence-free survival (RFS). A nomogram was developed based on these factors, and its performance was validated in the validation cohort. RFS was analyzed using Kaplan-Meier curves and the Log rank test. Results: The median RFS for the 134 patients was 45.7 months, with 41.8% of patients experiencing tumor recurrence after hepatectomy. Univariate Cox regression analysis identified hepatitis Be antigen (HBeAg) positivity, tumor size, tumor growth subtype, non-peripheral washout, nodule-in-nodule architecture, mosaic architecture, and intratumoral arteries as significant risk factors for RFS. Multivariate Cox regression analysis revealed that HBeAg positive, tumor growth subtype, non-peripheral washout, mosaic architecture, and internal arteries were independent prognostic factors for RFS in patients with solitary HCC without MVI. The nomogram based on these variables demonstrated good predictive accuracy, with concordance indices (C-index) of 0.740 and 0.701 in the training and validation cohorts, respectively. Additionally, patients in the high-risk group exhibited significantly lower RFS compared to those in the low-risk group. Conclusion: A model incorporating Gd-BOPTA-enhanced MRI and clinical features can effectively predict RFS in solitary HCC patients without MVI and assist in risk stratification for recurrence after hepatectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.